The ARID4B Knockout A-549 Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal population of A-549 cells with targeted disruption of the ARID4B gene. This knockout model facilitates loss-of-function studies of ARID4B in lung adenocarcinoma. The polyclonal format maintains genetic diversity while abolishing functional ARID4B expression. Researchers can utilize this tool to probe ARID4B-dependent transcriptional repression and chromatin remodeling. CRISPR/Cas9-mediated gene disruption provides a consistent and effective knockout for downstream functional analyses.
The host A-549 cell line, an epithelial adenocarcinoma line from a male donor, carries a KRAS G12S mutation and is a standard model for lung adenocarcinoma and respiratory epithelium. It retains key signaling pathways of non-small cell lung cancer. The ARID4B knockout in this background enables dissection of epigenetic mechanisms in a clinically relevant cancer context, particularly for studying chromatin modifiers that intersect with oncogenic signaling.
ARID4B is a subunit of the SIN3A histone deacetylase complex, which deacetylates histones to promote transcriptional repression. It interacts with SIN3A, HDAC1, HDAC2, RB1, and BRMS1. Functioning downstream of RB1 and E2F transcription factors, ARID4B represses E2F-responsive genes such as cyclins, thereby regulating cell cycle progression and differentiation. Disruption of ARID4B relieves this repression, enabling examination of de-repressed targets in cancer cells.
In the A-549 context, ARID4B knockout helps decipher epigenetic dysregulation associated with KRAS-driven lung adenocarcinoma. The loss of ARID4B may perturb histone acetylation balance, affecting proliferation, apoptosis, and differentiation. Since ARID4B bridges RB1 to the SIN3A complex, its absence could illuminate how chromatin remodeling impacts tumor cell fate and drug responses. This model is valuable for studying the interplay between chromatin modification and oncogenic signaling in lung cancer.
Applications include studying epigenetic regulation in lung adenocarcinoma, characterizing SIN3A complex function, and analyzing cell cycle and apoptosis mechanisms. The knockout cells are compatible with western blotting, RT-qPCR, ChIP-qPCR, immunofluorescence, flow cytometry, apoptosis assays, cell cycle analysis, and drug sensitivity testing. They also facilitate identification of ARID4B target genes and evaluation of therapeutic susceptibilities. For further information, contact Ascent Research.
